ONCT - Oncternal Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
+0.86 (+14.68%)
As of 1:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.56
Bid6.36 x 1000
Ask6.45 x 3000
Day's Range5.85 - 6.72
52 Week Range4.86 - 179.20
Avg. Volume37,400
Market Cap23.09M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

    Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that the reverse merger with GTx, Inc., closed on June 7, 2019. “We believe that the closing of the merger signifies a transformative event that will provide Oncternal with the opportunity to achieve its next level of corporate growth as we continue to advance our promising oncology drug candidates through development,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.

  • We're sorry this is all we were able to find about this topic.